Citation Impact
Citing Papers
Place of Cabergoline in Acromegaly: A Meta-Analysis
2011
Guidelines for Acromegaly Management: An Update
2009
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)
2009 Standout
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor
2009
Acromegaly
2006 Standout
Pegvisomant and cabergoline combination therapy in acromegaly
2012
The Antitumoral Effects of Somatostatin Analog Therapy in Acromegaly
2005
Dopamine Resistance of Prolactinomas
2003
Insulin-Like Growth Factors I and II. Peptide, Messenger Ribonucleic Acid and Gene Structures, Serum, and Tissue Concentrations*
1989 Standout
Pharmacotherapy or Surgery as Primary Treatment for Acromegaly?
2000
Review of Pharmacological Effects of Glycyrrhiza sp. and its Bioactive Compounds
2008 Standout
High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly
2011
Reevaluation of Conventional Pituitary Irradiation in the Therapy of Acromegaly
1999
Cushing's syndrome
2015 Standout
Molecular defects in the pathogenesis of pituitary tumours
2003
Prevalence of Vertebral Fractures in Men with Acromegaly
2008
Cabergoline Decreases Somatotroph Adenoma Size: A Case Report
2004
Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function
2005
Psychedelics
2016 Standout
Acromegaly
1990
Paradoxical Enhancement of Pituitary Growth Hormone (GH) Responsiveness to GH-Releasing Factor in the Face of High Somatostatin Tone*
1989
Long-Term Evaluation of Postoperative Acromegalic Patients in Remission with Previous and Newly Proposed Criteria
2005
Thyroid Volume and Serum Thyroglobulin Levels in Patients with Acromegaly: Correlation with Plasma Insulin-Like Growth Factor I Levels*
1988
Therapeutic Efficacy of the Somatostatin Analog SMS 201-995 (Octreotide) in Acromegaly
1990
Raloxifene decreases serum IGF-I in male patients with active acromegaly
2004
Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline
2013 Standout
What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?
1998 Standout
Insulin and insulin-like growth factor signalling in neoplasia
2008 Standout
MEDICAL TREATMENT OF PROLACTINOMAS
1999
Evaluation of Disease Status with Sensitive Measures of Growth Hormone Secretion in 60 Postoperative Patients with Acromegaly1
1998
Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment
1997
Cabergoline Therapy of Growth Hormone & Growth Hormone/Prolactin Secreting Pituitary Tumors
2004
A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development
1995
Acromegaly
1994
Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
2011 Standout
Nelson’s Syndrome: Complete Remission with Cabergoline but Not with Bromocriptine or Cyproheptadine Treatment
2004
Prolactinoma
2003
Recurrence of Hyperprolactinemia after Withdrawal of Dopamine Agonists: Systematic Review and Meta-Analysis
2009
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
2011 Standout
Epidermal Growth Factor Induces the Functional Expression of Dopamine Receptors in the GH3 Cell Line*
1991
Fertility and infertility: Definition and epidemiology
2018 Standout
Failure of radiotherapy in acromegaly
2001
Acromegaly: An Endocrine Society Clinical Practice Guideline
2014 Standout
Induction of laminitis by prolonged hyperinsulinaemia in clinically normal ponies
2007 Standout
Long-Acting Somatostatin Analog Therapy of Acromegaly: A Meta-Analysis
2005
Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status
2004
Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
2012
Pituitary pars intermedia dysfunction: equine Cushing's disease
2002
Autoradiographic localization of dopamine D1 and D2 receptors in rat nucleus accumbens: Resistance to differential rearing conditions
1991 Standout
Dopamine Receptor Expression and Function in Corticotroph Pituitary Tumors
2004
Effects of two different somatostatin analogs on glucose tolerance in acromegaly
2002
Growth-hormone and prolactin excess
1998
GROWTH HORMONE NEUROREGULATION AND ITS ALTERATIONS IN DISEASE STATES
1988
Alterations in body composition in acromegaly
2008
Surgical Treatment of Prolactin-Secreting Pituitary Adenomas: Early Results and Long-Term Outcome
2002
Cushing's syndrome
2006 Standout
Medical therapy for clinically non-functioning pituitary adenomas
2008
Drug Insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women
2006
Effect of Different Dopaminergic Agents in the Treatment of Acromegaly
1997
Growth hormone and the heart
2001
Plasma Insulin-Like Growth Factor-I/Somatomedin-C in Acromegaly: Correlation With the Degree of Growth Hormone Hypersecretion*
1988
Pituitary Tumor Registry: A Novel Clinical Resource1
2000
Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human*
1998 Standout
Endocrine Therapy of Breast and Prostate Cancer
1989
A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly
2008
Beneficial Effects of High Daily Dose Bromocriptine Treatment in Cushing's Disease.
1992
Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with Acromegaly
2002
Treatment of Acromegaly with Dopamine Agonists
1992
The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis.
1992 Standout
Recurrent prolactinoma and meningioma following irradiation and bromocriptine treatment
1985
Somatotroph Hyperplasia
1982
Optimizing Control of Acromegaly: Integrating a Growth Hormone Receptor Antagonist into the Treatment Algorithm
2003
Prolactin (PRL) and Its Receptor: Actions, Signal Transduction Pathways and Phenotypes Observed in PRL Receptor Knockout Mice
1998 Standout
Clinical Manifestations of Acromegaly
1992
The effects of putative 5-hydroxytryptamine receptor active agents ond-amphetamine self-administration in controls and rats with 5,7-dihydroxytryptamine median forebrain bundle lesion
1984
Effects of a new type of 5-HT receptor agonist on male rat sexual behavior
1981 StandoutNobel
Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management
2004 Standout
Characterization of the paradoxical growth hormone inhibitory effect of galanin in acromegaly.
1995
Endocrine profile of ergot alkaloids
1977
On the Mode of the Prolactin Release-Inhibiting Action of the Serotonin Receptor Blockers Metergoline, Methysergide, and Cyproheptadine*
1981
Cabergoline in the Treatment of Acromegaly: A Study in 64 Patients
1998
Failed Forensics: How Forensic Science Lost Its Way and How It Might Yet Find It
2008 Standout
Inhibitory effect of octreotide on growth hormone-induced IGF-I generation and organ growth in hypophysectomized rats
1991
Advances in the Treatment of Prolactinomas
2006
Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment
1997
Long-Term Treatment of Prolactin-Secreting Macroadenomas with Pergolide
2000
Surgical Treatment of Prolactin-Secreting Pituitary Adenomas: Early Results and Long-Term Outcome
2002
Prolactin-Lowering and -Releasing Drugs Mechanisms of Action and Therapeutic Applications
1983
Hyperprolactinemia in Men: Clinical and Biochemical Features and Response to Treatment
2003
Evaluation and application of a highly sensitive assay for serum growth hormone (GH) in the study of adult GH deficiency.
1995
Adverse Health Consequences of Performance-Enhancing Drugs: An Endocrine Society Scientific Statement
2013 Standout
Increased Prevalence of Radiological Spinal Deformities in Active Acromegaly: A Cross-Sectional Study in Postmenopausal Women
2005
Prolactin: Structure, Function, and Regulation of Secretion
2000 Standout
Dopamine-receptor agonists: Mechanisms underlying autoreceptor selectivity
1985 StandoutNobel
Role of Dopamine in the Regulation of Growth Hormone Secretion: Dopamine and Bromocriptine Augment Growth Hormone (GH)-Releasing Hormone-Stimulated GH Secretion in Normal Man
1987
Bromocriptine
1977
8-hydroxy-2-(di-n-propylamino)tetralin, 8-OH-DPAT, a potent and selective simplified ergot congener with central 5-HT-receptor stimulating activity
1982 StandoutNobel
Growth Factors and Cancer
1991 StandoutScience
Pretreatment with somatostatin analog SMS 201-995 potentiates growth hormone (GH) responsiveness to GH-releasing factor in short children.
1993
Bromocriptine
1979
Acromegaly: historical perspectives and current therapy
2001
Demonstration of Enhanced Potency of a Chimeric Somatostatin-Dopamine Molecule, BIM-23A387, in Suppressing Growth Hormone and Prolactin Secretion from Human Pituitary Somatotroph Adenoma Cells
2002
A Critical Analysis of Pituitary Tumor Shrinkage during Primary Medical Therapy in Acromegaly
2005
Long-Term Treatment of Prolactin-Secreting Macroadenomas with Pergolide
2000
Growth hormone for children with chronic kidney disease
2012
Dopamine receptor agonists: Mechanisms underlying autoreceptor selectivity II. Theoretical considerations
1985 StandoutNobel
Somatostatin and Somatostatin Analogue (SMS 201-995) in Treatment of Hormone-Secreting Tumors of the Pituitary and Gastrointestinal Tract and Non-Neoplastic Diseases of the Gut
1989
Reversible Hypopituitarism in Patients with Large Nonfunctioning Pituitary Adenomas*
1986
Dopamine Receptors: From Structure to Function
1998 Standout
Cocaine Receptors on Dopamine Transporters Are Related to Self-Administration of Cocaine
1987 StandoutScience
Nerve growth factor suppresses the transforming phenotype of human prolactinomas.
1993
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly-2011 Update
2011
Responses of Markers of Bone and Collagen Turnover to Exercise, Growth Hormone (GH) Administration, and GH Withdrawal in Trained Adult Males1
2000
Response of central monoaminergic neurons to lisuride: Comparison with LSD
1979
Hyperprolactinemia: Evaluation and Management
1992
Hallucinogens
2004 Standout
Works of G. Oppizzi being referenced
Lipid profile during rhGH therapy in pediatric renal transplant patients
2002
Microprolactinomas: Why requiem for surgery?
1996
Persistence of somatostatinergic tone in acromegaly
1995
Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?
1998
From macroprolactinoma to concomitant ACTH-PRL hypersecretion with Cushing’s disease
2000
Neurosurgery restores late GH rise after glucose-induced suppression in cured acromegalics
1999
Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status
2003
Effects of tamoxifen on GH and IGF-I levels in acromegaly
1997
CV 205-502 in acromegaly
1993
A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly
1999
Cushing’s disease and marked hyperprolactinemia in a patient with a pituitary macroadenoma: effectiveness of bromocriptine treatment
1984
Lisuride Hydrogen Maleate: Evidence for a Long Lasting Dopaminergic Activity in Humans
1978
Effects of Nomifensine on Growth Hormone and Prolactin Secretion in Normal Subjects and in Pathological Hyperprolactinemia*
1982
Stable Reduction of Plasma Growth Hormone (hGH) Levels During Chronic Administration of 2-Br-α-ergocryptine (CB-154) in Acromegalic Patients
1975
Role of dopaminergic receptors in the regulation of growth hormone secretion.
1977
Chronic Treatment of Pathological Hyperprolactinemia and Acromegaly with the New Ergot Derivative Terguride*
1986
Effect of chronic bromocriptine administration on tumor size in patients with “nonsecreting” pituitary adenomas
1985
Relationship between Somatomedin-C and Growtyh Hormone Levels in Acromegaly: Basal and Dynamic Evaluation*
1986
Evidence for octreotide subcutaneously in the treatment of acromegaly.
1997
Effect of the new ergot derivative terguride on plasma PRL and GH levels in patients with pathological hyperprolactinemia or acromegaly
1985
Serum Type III Procollagen Propeptide Levels in Acromegalic Patients*
1986
Low Doses of Dopamine Agonists in the Long-Term Treatment of Macroprolactinomas
1985
Reenlargement of macroprolactinomas during bromocriptine treatment: report of two cases
1983
EVIDENCE FOR A DOPAMINERGIC ACTIVITY OF METHYSERGIDE IN HUMANS
1977
Size Reduction of Macroprolactinomas by Bromocriptine or Lisuride Treatment*
1981
Medical Treatment of Acromegaly with SMS 201-995, a Somatostatin Analog: A Comparison with Bromocriptine*
1987
Changes in Growth Hormone (GH) Secretion Induced by Human Pancreatic GH Releasing Hormone-44 in Acromegaly: A Comparison with Thyrotropin-Releasing Hormone and Bromocriptine*
1985
Bromocriptine Does Not Alter Growth Hormone (GH) Responsiveness to GH-Rreleasing Hormone in Accromegaly*
1986
Inhibitory Effect of an Ergoline Derivative, Methergoline, on Growth Hormone and Prolactin Levels in Acromegalic Patients
1976
EFFECT OF DOPAMINE INFUSION ON PLASMA LEVELS OF GROWTH HORMONE IN NONMAL SUBJECTS AND IN AGROMEGALIC PATIENTS
1976